{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,18]],"date-time":"2026-11-18T13:02:21Z","timestamp":1795006941682,"version":"4.9.1"},"reference-count":22,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"8","license":[{"start":{"date-parts":[[2019,8,1]],"date-time":"2019-08-01T00:00:00Z","timestamp":1564617600000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2019,8]]},"abstract":"<jats:sec>\n                    <jats:title>Background:<\/jats:title>\n                    <jats:p>Ceftazidime-avibactam plus metronidazole is effective in the treatment of complicated intra-abdominal infection (cIAI) in adults. This single-blind, randomized, multicenter, phase 2 study (NCT02475733) evaluated the safety, efficacy and pharmacokinetics of ceftazidime-avibactam plus metronidazole in children with cIAI.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods:<\/jats:title>\n                    <jats:p>Hospitalized children (\u22653 months to &lt;18 years) with cIAI were randomized 3:1 to receive intravenous ceftazidime-avibactam plus metronidazole, or meropenem, for a minimum of 72 hours (9 doses), with optional switch to oral therapy thereafter for a total treatment duration of 7\u201315 days. Safety and tolerability were assessed throughout the study, along with clinical and microbiologic outcomes, and pharmacokinetics. A blinded observer determined adverse event (AE) causality, and clinical outcomes up to the late follow-up visit.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results:<\/jats:title>\n                    <jats:p>\n                      Eighty-three children were randomized and received study drug (61 ceftazidime-avibactam plus metronidazole and 22 meropenem); most (90.4%) had a diagnosis of appendicitis. Predominant Gram-negative baseline pathogens were\n                      <jats:italic toggle=\"yes\">Escherichia coli<\/jats:italic>\n                      (79.7%) and\n                      <jats:italic toggle=\"yes\">Pseudomonas aeruginosa<\/jats:italic>\n                      (33.3%); 2\n                      <jats:italic toggle=\"yes\">E. coli<\/jats:italic>\n                      isolates were ceftazidime-non-susceptible. AEs occurred in 52.5% and 59.1% of patients in the ceftazidime-avibactam plus metronidazole and meropenem groups, respectively. Serious AEs occurred in 8.2% and 4.5% of patients, respectively; none was considered drug related. No deaths occurred. Favorable clinical\/microbiologic responses were observed in \u226590% of patients in both treatment groups at end-of-intravenous treatment and test-of-cure visits.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions:<\/jats:title>\n                    <jats:p>Ceftazidime-avibactam plus metronidazole was well tolerated, with a safety profile similar to ceftazidime alone, and appeared effective in pediatric patients with cIAI due to Gram-negative pathogens, including ceftazidime-non-susceptible strains.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1097\/inf.0000000000002392","type":"journal-article","created":{"date-parts":[[2019,7,15]],"date-time":"2019-07-15T08:20:46Z","timestamp":1563178846000},"page":"816-824","source":"Crossref","is-referenced-by-count":76,"title":["Safety and Efficacy of Ceftazidime-Avibactam Plus Metronidazole in the Treatment of Children \u22653 Months to &lt;18 Years With Complicated Intra-Abdominal Infection: Results From a Phase 2, Randomized, Controlled Trial"],"prefix":"10.1097","volume":"38","author":[{"given":"John S.","family":"Bradley","sequence":"first","affiliation":[{"name":"Rady Children\u2019s Hospital\/University of California San Diego School of Medicine, San Diego, CA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Helen","family":"Broadhurst","sequence":"additional","affiliation":[{"name":"AstraZeneca, Alderley Park, Macclesfield, United Kingdom"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Karen","family":"Cheng","sequence":"additional","affiliation":[{"name":"Pfizer, Sandwich, Kent, United Kingdom"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maria","family":"Mendez","sequence":"additional","affiliation":[{"name":"Hospital Universitari Germans Trias i Pujol, Barcelona, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paul","family":"Newell","sequence":"additional","affiliation":[{"name":"AstraZeneca, Alderley Park, Macclesfield, United Kingdom"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Martin","family":"Prchlik","sequence":"additional","affiliation":[{"name":"Thomayerova Nemocnice, Prague, Czech Republic"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gregory G.","family":"Stone","sequence":"additional","affiliation":[{"name":"Pfizer, Groton, CT"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Angela K.","family":"Talley","sequence":"additional","affiliation":[{"name":"Allergan plc, Madison, NJ"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Margaret","family":"Tawadrous","sequence":"additional","affiliation":[{"name":"Pfizer, Groton, CT"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dalia","family":"Wajsbrot","sequence":"additional","affiliation":[{"name":"Pfizer, New York, NY"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Katrina","family":"Yates","sequence":"additional","affiliation":[{"name":"AstraZeneca, Alderley Park, Macclesfield, United Kingdom"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Antonina","family":"Zuzova","sequence":"additional","affiliation":[{"name":"Smolensk State Medical University, Smolensk, Russia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Annie","family":"Gardner","sequence":"additional","affiliation":[{"name":"Pfizer, Cambridge, MA."}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","reference":[{"key":"R1-20230912","doi-asserted-by":"crossref","first-page":"79","DOI":"10.1089\/sur.2009.9930","article-title":"Diagnosis and management of complicated intra-abdominal infection in adults and children: guidelines by the Surgical Infection Society and the Infectious Diseases Society of America.","volume":"11","author":"Solomkin","year":"2010","journal-title":"Surg Infect (Larchmt)"},{"key":"R2-20230912","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1186\/s13017-017-0141-6","article-title":"The management of intra-abdominal infections from a global perspective: 2017 WSES guidelines for management of intra-abdominal infections.","volume":"12","author":"Sartelli","year":"2017","journal-title":"World J Emerg Surg"},{"key":"R3-20230912","doi-asserted-by":"crossref","first-page":"720","DOI":"10.1080\/00365540903159261","article-title":"Community-acquired complicated intra-abdominal infections in children hospitalized during 1995-2004 at a paediatric surgery department.","volume":"41","author":"Newman","year":"2009","journal-title":"Scand J Infect Dis"},{"key":"R4-20230912","doi-asserted-by":"crossref","first-page":"579","DOI":"10.1016\/j.ijantimicag.2017.01.010","article-title":"A randomised, double-blind, phase 3 study comparing the efficacy and safety of ceftazidime\/avibactam plus metronidazole versus meropenem for complicated intra-abdominal infections in hospitalised adults in Asia.","volume":"49","author":"Qin","year":"2017","journal-title":"Int J Antimicrob Agents"},{"key":"R5-20230912","doi-asserted-by":"crossref","first-page":"1380","DOI":"10.1093\/cid\/ciw133","article-title":"Efficacy and safety of ceftazidime-avibactam plus metronidazole versus meropenem in the treatment of complicated intra-abdominal infection: results from a randomized, controlled, double-blind, phase 3 program.","volume":"62","author":"Mazuski","year":"2016","journal-title":"Clin Infect Dis"},{"key":"R6-20230912","first-page":"72","article-title":"Epidemiology and antimicrobial susceptibility of gram-negative pathogens causing intra-abdominal infections in pediatric patients in Europe-SMART 2011-2014.","volume":"6","author":"Lob","year":"2017","journal-title":"J Pediatric Infect Dis Soc"},{"key":"R7-20230912","doi-asserted-by":"crossref","first-page":"894","DOI":"10.1089\/sur.2017.104","article-title":"Low infection-related re-admission rates in a retrospective of 4725 children with appendicitis using a clinical pathway in a tertiary care pediatric center.","volume":"18","author":"Marino","year":"2017","journal-title":"Surg Infect (Larchmt)"},{"key":"R8-20230912","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1186\/2047-2994-1-11","article-title":"Ready for a world without antibiotics? The Pensi\u00e8res antibiotic resistance call to action.","volume":"1","author":"Carlet","year":"2012","journal-title":"Antimicrob Resist Infect Control"},{"issue":"suppl)","key":"R11-20230912","doi-asserted-by":"crossref","first-page":"S41","DOI":"10.1016\/j.jinf.2016.04.021","article-title":"Beta-lactamases in Enterobacteriaceae infections in children.","volume":"72","author":"Moxon","year":"2016","journal-title":"J Infect"},{"key":"R12-20230912","doi-asserted-by":"crossref","first-page":"1789","DOI":"10.1128\/AAC.04191-14","article-title":"In vitro susceptibility of characterized \u03b2-lactamase-producing strains tested with avibactam combinations.","volume":"59","author":"Li","year":"2015","journal-title":"Antimicrob Agents Chemother"},{"key":"R13-20230912","doi-asserted-by":"crossref","first-page":"326","DOI":"10.1093\/jac\/dkp197","article-title":"In vitro activity of the \u03b2-lactamase inhibitor NXL104 against KPC-2 carbapenemase and Enterobacteriaceae expressing KPC carbapenemases.","volume":"64","author":"Stachyra","year":"2009","journal-title":"J Antimicrob Chemother"},{"key":"R14-20230912","doi-asserted-by":"crossref","first-page":"2713","DOI":"10.1093\/jac\/dkw239","article-title":"Spotlight on ceftazidime\/avibactam: a new option for MDR Gram-negative infections.","volume":"71","author":"Falcone","year":"2016","journal-title":"J Antimicrob Chemother"},{"key":"R15-20230912","doi-asserted-by":"crossref","first-page":"661","DOI":"10.1016\/S1473-3099(16)30004-4","article-title":"Ceftazidime-avibactam or best available therapy in patients with ceftazidime-resistant Enterobacteriaceae and Pseudomonas aeruginosa complicated urinary tract infections or complicated intra-abdominal infections (REPRISE): a randomised, pathogen-directed, phase 3 study.","volume":"16","author":"Carmeli","year":"2016","journal-title":"Lancet Infect Dis"},{"key":"R16-20230912","doi-asserted-by":"crossref","first-page":"1183","DOI":"10.1093\/jac\/dks523","article-title":"Comparative study of the efficacy and safety of ceftazidime\/avibactam plus metronidazole versus meropenem in the treatment of complicated intra-abdominal infections in hospitalized adults: results of a randomized, double-blind, Phase II trial.","volume":"68","author":"Lucasti","year":"2013","journal-title":"J Antimicrob Chemother"},{"key":"R19-20230912","doi-asserted-by":"crossref","first-page":"318","DOI":"10.1128\/AAC.26.3.318","article-title":"Ceftazidime as initial therapy for suspected bacterial infections in hospitalized pediatric patients.","volume":"26","author":"Reed","year":"1984","journal-title":"Antimicrob Agents Chemother"},{"key":"R22-20230912","doi-asserted-by":"crossref","first-page":"549","DOI":"10.1097\/INF.0000000000001859","article-title":"Ceftazidime-avibactam antimicrobial activity and spectrum when tested against gram-negative organisms from pediatric patients: results from the INFORM surveillance program (United States, 2011-2015).","volume":"37","author":"Sader","year":"2018","journal-title":"Pediatr Infect Dis J"},{"key":"R23-20230912","doi-asserted-by":"crossref","first-page":"6252","DOI":"10.1128\/AAC.00862-16","article-title":"Phase I study assessing the pharmacokinetic profile, safety, and tolerability of a single dose of ceftazidime-avibactam in hospitalized pediatric patients.","volume":"60","author":"Bradley","year":"2016","journal-title":"Antimicrob Agents Chemother"},{"key":"R26-20230912","doi-asserted-by":"crossref","first-page":"629","DOI":"10.1681\/ASN.2008030287","article-title":"New equations to estimate GFR in children with CKD.","volume":"20","author":"Schwartz","year":"2009","journal-title":"J Am Soc Nephrol"},{"issue":"suppl 1","key":"R29-20230912","doi-asserted-by":"crossref","first-page":"S16","DOI":"10.1086\/647939","article-title":"Metronidazole is still the drug of choice for treatment of anaerobic infections.","volume":"50","author":"L\u00f6fmark","year":"2010","journal-title":"Clin Infect Dis"},{"key":"R30-20230912","doi-asserted-by":"crossref","first-page":"285","DOI":"10.1016\/S1473-3099(17)30747-8","article-title":"Ceftazidime-avibactam versus meropenem in nosocomial pneumonia, including ventilator-associated pneumonia (REPROVE): a randomised, double-blind, phase 3 non-inferiority trial.","volume":"18","author":"Torres","year":"2018","journal-title":"Lancet Infect Dis"},{"key":"R31-20230912","doi-asserted-by":"crossref","first-page":"754","DOI":"10.1093\/cid\/ciw378","article-title":"Ceftazidime-avibactam versus doripenem for the treatment of complicated urinary tract infections, including acute pyelonephritis: RECAPTURE, a phase 3 randomized trial program.","volume":"63","author":"Wagenlehner","year":"2016","journal-title":"Clin Infect Dis"},{"key":"R32-20230912","doi-asserted-by":"crossref","first-page":"172","DOI":"10.1111\/j.1745-7599.2008.00305.x","article-title":"Predisposing factors to phlebitis in patients with peripheral intravenous catheters: a descriptive study.","volume":"20","author":"Uslusoy","year":"2008","journal-title":"J Am Acad Nurse Pract"}],"container-title":["Pediatric Infectious Disease Journal"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.lww.com\/00006454-201908000-00010","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,9,12]],"date-time":"2023-09-12T18:55:50Z","timestamp":1694544950000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/00006454-201908000-00010"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,8]]},"references-count":22,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2019]]}},"URL":"https:\/\/doi.org\/10.1097\/inf.0000000000002392","relation":{"has-review":[{"id-type":"doi","id":"10.3410\/f.736255596.793564015","asserted-by":"object"}]},"ISSN":["0891-3668"],"issn-type":[{"value":"0891-3668","type":"print"}],"subject":[],"published":{"date-parts":[[2019,8]]}}}